Nanjing Vazyme Biotech Stock Forum

The company's low P/S ratio may be due to poor revenue performance and expectations that this will continue, which could impact the future direction of the share price. The company's outlook for shrinking revenue is contributing to its low P/S. Given these circumstances, it's hard to see the share price rising strongly in the near future.

Possible overvaluation of Nanjing Vazyme Biotech's shares due to declining revenues, despite lift in share price and P/S ratio. Investors may be paying a premium for the stock, which may not be sustainable.